Biotech startups operate in a highly demanding communication environments. You are expected to demonstrate scientific credibility, commercial relevance, and ethical responsibility; most of it even before market entry. This is why a science marketing strategy for biotech startups cannot be improvised or copied from general consumer brands. It must be designed specifically for scientific audiences, long development timelines, and trust-based decision making.

B2B marketing in the sciences is definitely different to generic marketing. Not only are scientific discoveries and biotechnology developments complex, but they are also often taking a long time, have high stakes, and require trust by customers and/or end-users. Thus, if you want to market to scientists, engineers, clinicians, or technically literate decision-makers, traditional B2B marketing playbooks will fail you.

Communicating science clearly and effectively isn’t always easy, but given that funding, investments, and sales depend on how well you communicate, the need for science communication is non-negotiable. This can be made easier by bringing in external creative teams with expertise and experience in how to showcase your science through excellent science communication.

Over the past decade, China has transformed its pharmaceutical sector, evolving from a generics-dominated market into a global engine for innovative drug development. This shift has been driven by a combination of regulatory reforms, substantial increases in research and development (R&D) investment, and the rapid expansion of clinical research and manufacturing capabilities. This article explores the key drivers behind China’s rise in innovative drug development.

Because science podcasts are no longer a “nice to have” marketing asset, but, when strategically used, become durable evergreen assets within a broader science marketing strategy. And drive trust, discoverability, and long-term authority. In this post, we compare three science podcast case studies of work that we created to highlight that different podcast formats: independent, application-focused, and technology-driven, can deliver measurable value when aligned with a clear

Innovation in cell and gene therapy depends on scientific breakthroughs as well as enabling technologies that address key challenges in delivery, safety, and development efficiency. At the ELRIG Cell and Gene Therapy 2026 conference, a number of emerging technology developers showcased solutions designed to overcome some of the most persistent bottlenecks in the field.